Document Detail


Contragestion with RU 486: a new approach to postovulatory fertility control.
MedLine Citation:
PMID:  2694738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The steroidal derivative RU 486 (17 beta-hydroxy-11 beta-(4-dimethyl-aminophenyl)-17 alpha-(prop-1-ynyl) ester-4, 9-dien-3-one) is the first potent antiprogestin to be used clinically. RU 486 blocks the action of progesterone by a reversible inhibition of the action of progesterone on its own receptors. This reversibility allows endocrine functions to return quickly to normal after discontinuation of treatment. However, target cells which depend upon a continuity of progesterone action will be irreversibly disrupted by receptor blockade. In normal women, RU 486 acts during the luteal phase in the endometrium, provoking bleeding, and decreasing pituitary luteinizing hormone (LH) secretion and hence luteolysis. In pregnant women, it affects the decidua, increases myometrial contractility and ripening of the cervix and ultimately leads to termination of pregnancy. Detachment of the trophoblast leads to a further fall in gonadotropin production. Clinical studies indicate that RU 486 can be a very efficient agent for the termination of early pregnancy, and as a postcoital menstrual regulator. In about 20% of cases when RU 486 is given alone, termination of pregnancy fails. This can be overcome by taking in addition a small amount of prostaglandin.
Authors:
E E Baulieu
Related Documents :
15336698 - Biosynthesis and catabolism of prostaglandin f2alpha (pgf2alpha) are controlled by prog...
12968948 - Enzymeimmunoassay of oestradiol, testosterone and progesterone in urine samples from fe...
21273398 - Predictors of measurement error in energy intake during pregnancy.
24404798 - Associations of maternal asthma severity and control with pregnancy complications.
23524238 - Placental abc transporters, cellular toxicity and stress in pregnancy.
22982718 - Relation of circulating t cell profiles to airway inflammation and asthma control in as...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica. Supplement     Volume:  149     ISSN:  0300-8835     ISO Abbreviation:  Acta Obstet Gynecol Scand Suppl     Publication Date:  1989  
Date Detail:
Created Date:  1990-03-07     Completed Date:  1990-03-07     Revised Date:  2008-02-21    
Medline Journal Info:
Nlm Unique ID:  0337655     Medline TA:  Acta Obstet Gynecol Scand Suppl     Country:  SWEDEN    
Other Details:
Languages:  eng     Pagination:  5-8     Citation Subset:  IM    
Affiliation:
INSERM U 33, Bicêtre, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials as Topic
Female
Humans
Mifepristone* / administration & dosage,  pharmacology
Pregnancy
Progesterone / antagonists & inhibitors
Terminology as Topic
Chemical
Reg. No./Substance:
57-83-0/Progesterone; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  RU 486 (mifepristone): clinical trials in China.
Next Document:  Clinical trials with RU 486 (mifepristone): an update.